What do systematic reviews say?

Botulinum toxin type A vs placebo

The review found no eligible studies for this question.

• Botulinum toxin type A therapy for blepharospasm 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Other NSAIDs vs placebo

The review found no eligible studies for this question.

• Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Celecoxib vs placebo

The review found no eligible studies for this question.

• Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Aspirin vs placebo

The review found no eligible studies for this question.

• Aspirin and other non‐steroidal anti‐inflammatory drugs for the prevention of dementia 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings for resveratrol plus oral anti‐diabetic drugs vs placebo plus oral anti‐diabetic drugs

The review found no eligible studies for this question.

• Resveratrol for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

N‐acetylcysteine vs placebo

The review found no eligible studies for this question.

• N‐acetylcysteine for non‐paracetamol (acetaminophen)‐related acute liver failure 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pazopanib vs placebo (targeted agent versus placebo)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 300 participants
  High

Topical antibiotics vs placebo/no treatment

The review found no eligible studies for this question.

• Topical antibiotics for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical antibiotics with steroids vs placebo/no treatment

The review found no eligible studies for this question.

• Topical antibiotics with steroids for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Serlopitant 0.25 mg vs placebo

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Serlopitant 5 mg vs placebo

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 127 participants
  Very low

Serlopitant 1 mg vs placebo

• Interventions for chronic pruritus of unknown origin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 128 participants
  Very low

Atorvastatin vs placebo

The review found no eligible studies for this question.

• Statins for asthma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: pioglitazone monotherapy vs placebo

The review found no eligible studies for this question.

• Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

5‐ASA vs placebo

The review found no eligible studies for this question.

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

MSCs vs placebo or control

The review found no eligible studies for this question.

• Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft‐versus‐host disease in haematopoietic… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs placebo plus antidepressant

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo

The review found no eligible studies for this question.

• Pharmacological interventions for treatment‐resistant depression in adults 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found